Enhancement of the endothelial production of prostacyclin by substituted derivatives of BAPTA-AM.
Our observation that loading of bovine aortic endothelial cells with quin 2 or 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) enhances their release of prostacyclin (PGI2) has been studied in detail. The action of the acetoxymethyl ester (AM) of BAPTA (BAPTA-AM) was biphasic: at high concentrations (50 microM) and after prolonged exposure (60 min or more), it behaved as an inhibitor instead of an amplifier. Since inhibition could be related to calcium chelation, we tested 5,5'-difluoro-BAPTA-AM (5FBAPTA-AM), 4,4'-difluoro-BAPTA-AM (4FBAPTA-AM) and 5,5'-dibromo-BAPTA-AM (5BBAPTA-AM), whose corresponding free acids have a reduced affinity for Ca2+: these compounds were much more active in enhancing PGI2 production than BAPTA-AM itself. The effect of 5BBAPTA-AM was detectable at 0.5 microM and almost maximal at 5 microM (5-fold increase). 5BBAPTA-AM increased the release of free arachidonate induced by ATP but had no effect on the generation of inositol phosphates, the release of choline metabolites, and the accumulation of cAMP. 5BBAPTA-AM had a cytotoxic effect on the endothelial cells only after prolonged exposure to a high (50 microM) concentration. 5BBAPTA-AM inhibited the platelet production of thromboxane stimulated by a high (0.5 U/ml) concentration of thrombin and slightly potentiated the effect of a low (0.005 U/ml) concentration. In conclusion, the effect of 5BBAPTA-AM on the production of PGI2 seems to be rather specific to arachidonate metabolism in endothelial cells.
Institute of Interdisciplinary Research, School of Medicine, Université Libre de Bruxelles, Belgium.
J M
JM
Boeynaems
S
S
Heilporn
F
F
Broeders
J C
JC
Braekman
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002417:Cattle; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002794:Choline / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D011464:Epoprostenol / Q000096:biosynthesis*; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism; D013929:Thromboxane B2 / Q000378:metabolism
C080783:1,2-bis(2-aminophenoxy)ethane-4,4'-difluoro-N,N,N',N'-tetraacetic acid acetoxymethyl ester; C080780:1,2-bis(2-aminophenoxy)ethane-5,5'-dibromo-N,N,N',N'-tetraacetic acetoxymethyl ester; C080781:1,2-bis(2-aminophenoxy)ethane-5,5'-difluoro-N,N,N',N'-tetraacetic acid acetoxymethyl ester; D007295:Inositol Phosphates; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D016718:Arachidonic Acid; D004533:Egtazic Acid; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D000242:Cyclic AMP; D002794:Choline; D002118:Calcium